Study of Systemic Lupus Erythematosus
NCT00001372 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000
Last updated 2026-05-22
Summary
This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their relatives to learn more about how the disease develops and changes over time. It will also study genetic factors that make a person susceptible to SLE.
Patients 3 years of age and older with known or suspected SLE and their relatives may be eligible for this study. Patients will be evaluated with a medical history and physical examination, blood and urine tests. Other procedures may include:
1. Electrocardiogram
2. 24-hour urine collection
3. Imaging studies, such as chest and joint X-rays, magnetic resonance imaging (MRI) scans, bone scans, and bone densitometry.
4. Questionnaire about the degree of disease activity, and survey of risk factors for disease complications.
5. Apheresis-Collection of plasma (fluid portion of blood) or blood cells for analysis. Whole blood is collected through a needle in an arm vein. The blood circulates through a machine that separates it into its components. The required component (plasma or cells) is removed and the rest of the blood is returned to the body through the same needle or through a second needle in the other arm.
6. Skin biopsy-Removal of a small skin sample for microscopic analysis. An area of skin is numbed with an anesthetic and a small circular portion (about 1/4 inch in diameter) is removed, using a sharp cookie cutter-type instrument.
7. Kidney, bone marrow or other organ biopsy-Removal of a small sample of organ tissue. These biopsies are done only if they can provide information useful in better understanding the disease or making treatment decisions.
8. Genetic studies-Collection of a blood sample for gene testing.
Patients will be followed at least once a year with a brief history and physical examination and routine blood and urine tests. Some patients may be seen more often. Treatment recommendations will be offered to patients' physicians, and patients who are eligible for other research treatment studies will be invited to enroll.
Participating relatives of patients will fill out a brief medical history questionnaire and provide a DNA sample (either a blood sample or tissue swab from the inside of the cheek) for genetic testing.
Conditions
Sponsors & Collaborators
-
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
lead NIH
Principal Investigators
-
Sarfaraz A Hasni, M.D. · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Eligibility
- Min Age
- 3 Years
- Max Age
- 120 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 1994-02-10
Countries
- United States
Study Locations
More Related Trials
-
Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE
NCT01702038 ·Status: WITHDRAWN ·Phase: PHASE2
-
Lupus Cohort--Thrombotic Events and Coronary Artery Disease
NCT00005436 ·Status: COMPLETED
-
A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus
NCT02725515 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of Clinical and Serological Differences Among Juvenile, Adult, and Late-onset Systemic Lupus Erythematosus
NCT05724940 ·Status: UNKNOWN
-
Role of Antibodies in Cognitive Dysfunction in Patients With Systemic Lupus Erythematosus
NCT00042523 ·Status: COMPLETED
-
An Investigation of NNC 0151-0000-0000 in Subjects With Systemic Lupus Erythematosus (SLE)
NCT01018238 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers
NCT02034344 ·Status: COMPLETED
-
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
NCT00137969 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE)
NCT06791772 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
NCT07175285 ·Status: RECRUITING
-
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
NCT04961567 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
New Signaling Pathway Targeting Systemic Lupus Erythematosus
NCT03984227 ·Status: UNKNOWN
-
Study of the Role of Soluble Forms of RAGE (sRAGE/esRAGE) as Diagnostic and Prognostic Biomarkers of Systemic Lupus Erythematosus.
NCT02891213 ·Status: UNKNOWN
-
Systemic Lupus Erythematosus in Gullah Health
NCT00756769 ·Status: RECRUITING
-
Epidemiologic Study of Reproductive Outcome in Women With Systemic Lupus Erythematosus
NCT00004663 ·Status: COMPLETED
-
Anemia in Systemic Lupus Erythematosus Specially Refractory Type
NCT06210295 ·Status: NOT_YET_RECRUITING
-
Anti-CD20 in Systemic Lupus Erythematosus
NCT00036491 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Utilizing Qualitative and Quantitative Methods to Understand a New Model of Type 1 and 2 Systemic Lupus Erythematosus (SLE)
NCT05426902 ·Status: COMPLETED ·Phase: NA
-
A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus
NCT05866861 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Translation of a Diagnostic Test for Lupus Flare Prediction From Bench to Clinic
NCT04018222 ·Status: UNKNOWN
-
Cutaneous Lupus Registry
NCT01266915 ·Status: RECRUITING
-
Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus
NCT00556192 ·Status: COMPLETED ·Phase: PHASE2
-
An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus
NCT03252587 ·Status: COMPLETED ·Phase: PHASE2
-
Lupus Landmark Study: A Prospective Registry and Biorepository
NCT05934149 ·Status: RECRUITING
-
Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus
NCT01405196 ·Status: COMPLETED ·Phase: PHASE2